A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer
A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer
Jordi Rodón, MD, PhD
(Hospital Universitario Vall d'Hebron, Barcelona)